Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00948220
Recruitment Status : Completed
First Posted : July 29, 2009
Last Update Posted : June 7, 2011
Hoffmann-La Roche
Information provided by:
University of Ulm

Brief Summary:
One single study has suggested that bone mineral density (BMD) is reduced in patients with non-cirrhotic chronic viral hepatitis C. Antiviral combination therapy with standard interferon and ribavirin may further decrease BMD. The aim of this study is to systematically investigate the effect of chronic hepatitis C genotype 1 infection alone and current standard therapy with peginterferon alfa-2a/ribavirin on BMD and bone metabolism.

Condition or disease Intervention/treatment Phase
Hepatitis C, Chronic Liver Diseases Virus Diseases Drug: peginterferon alfa-2a and ribavirin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Non-randomized Prospective Study on the Effect of Antiviral Therapy With Peginterferon Alfa-2a and Ribavirin on Bone Mineral Density and Metabolism in Patients With Chronic Viral Hepatitis C Genotype 1
Study Start Date : July 2003
Actual Primary Completion Date : January 2007
Actual Study Completion Date : March 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment
Chronic hepatitis C patients on standard antiviral therapy with peginterferon alfa-2a and ribavirin
Drug: peginterferon alfa-2a and ribavirin
standard antiviral therapy with peginterferon alfa-2a 180 µg/week and ribavirin 1000-1200 mg/d
Other Names:
  • Pegasys
  • Copegus

No Intervention: Control
Chronic hepatitis C patients without standard antiviral therapy

Primary Outcome Measures :
  1. Change of the bone mineral density of the lumbar spine and right hip measured by DEXA in patients with chronic hepatitis C with or without antiviral combination treatment with peginterferon and ribavirin [ Time Frame: 96 weeks ]

Secondary Outcome Measures :
  1. Change in markers of bone formation and resorption over time during antiviral therapy and after cessation of therapy. [ Time Frame: 96 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • proven chronic hepatitis C
  • aged between 18 and 65
  • male patients

Exclusion Criteria:

  • high grade liver fibrosis (Grade 3 - 4)
  • renal disease
  • hyperparathyroidism
  • hypogonadism
  • malignant disease
  • use of any other drug known to effect bone mineral metabolism
  • use of alcohol
  • organ transplant
  • any form of thyroid disease
  • any medical condition known to be associated with bone loss

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00948220

Layout table for location information
University Hospital Ulm
Ulm, Germany, 89081
Sponsors and Collaborators
University of Ulm
Hoffmann-La Roche
Layout table for investigator information
Principal Investigator: Michael Fuchs, MD University of Ulm

Layout table for additonal information
Responsible Party: Dr. med. D. Klass, Universitätsklinikum Ulm Identifier: NCT00948220    
Other Study ID Numbers: OSTEO
First Posted: July 29, 2009    Key Record Dates
Last Update Posted: June 7, 2011
Last Verified: May 2011
Keywords provided by University of Ulm:
hepatitis C virus
chronic hepatitis c
bone mineral density
Bone Density
Hepatitis, Viral, Human
Anti-Infective Agents
peginterferon alfa-2a
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Liver Diseases
Virus Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Hepatitis, Chronic
Antiviral Agents
Peginterferon alfa-2a
Molecular Mechanisms of Pharmacological Action
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs